Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.52 |
| ▸ | PRF1 | P14222 | 16/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2053386 | 0.90 | NOTUM (0.52) | NOTUMPRF1ACHEMAPT | |
| SCHEMBL14761086 | 0.77 | PRF1 (0.65) | PRF1LMNAGAAMAPT | |
| SCHEMBL2019067 | 0.76 | PRF1 (0.55) | PRF1ACHELMNAGAAMAPT | |
| SCHEMBL17055774 | 0.71 | NOTUM (0.56) | NOTUMLMNAMAPT | |
| SCHEMBL1702314 | 0.70 | PRF1 (0.65) | PRF1ACHELMNAGAAMAPT | |
| SCHEMBL29861325 | 0.70 | PRF1 (0.65) | PRF1ACHELMNAGAAMAPT | |
| SCHEMBL1313626 | 0.70 | NOTUM (1.00) | NOTUMLMNAMAPT | |
| SCHEMBL12633609 | 0.70 | PRF1 (0.57) | PRF1ACHELMNAGAAMAPT | |
| SCHEMBL2020077 | 0.69 | PRF1 (0.53) | PRF1ACHELMNAGAAMAPT | |
| SCHEMBL3233333 | 0.69 | NOTUM (0.72) | NOTUMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-03-14 | — | — | US | disclosed |
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-03-14 | — | — | US | disclosed |
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-03-14 | — | — | US | disclosed |
| EP-2515903-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | Peter MacCallum Cancer Institute (AU) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011075784-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011075784-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, SERPINB1 | NOTUM 1823/4885PRF1 1/4885ACHE 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.